| Identification | Back Directory | [Name]
Ziconotide Acetate | [CAS]
914454-03-8 | [Synonyms]
Prialt Acetate
ω-Conotoxin M VIIA Acetate
ω-Conopeptide MVIIA Acetate | [Molecular Formula]
C104H176N36O34S7 | [MOL File]
914454-03-8.mol | [Molecular Weight]
2699.19 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C, protect from light, stored under nitrogen | [solubility ]
DMSO : 25 mg/mL (Need ultrasonic) | [form ]
Solid | [color ]
White to off-white | [Sequence]
Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cys-NH2 (Disulfide bridge:Cys1-Cys16;Cys8-Cys20;Cys15-Cys25) |
| Hazard Information | Back Directory | [Uses]
Ziconotide Acetate is a selective antagonist of N-type voltage sensitive calcium channels (VSCC). Blocks neurotransmitter release by preventing depolarization-induced calcium influx. Used as a ligand for binding studies of voltage sensitive calcium channels. it can be used for analgesic.
| [in vivo]
Ziconotide (i.t.; 25-100 pmol/site; 5 μL; on the 4 th, 10 th, 15 th, 20 th, and 24 th days) acetate reduces the levels of IL-1β and IL-23 in the CNS, as well as IL-17 production in the spleen, 25 days after MOG35-55-elicited EAE, in the mouse model of experimental autoimmune encephalomyelitis (EAE)[2]. | Animal Model: | Female C57BL/6mice (18-22 g, 6-8 weeks old) injected with myelin oligodendrocytes glycoprotein[2] | | Dosage: | 25 pmol/site, 50 pmol/site, 100 pmol/site | | Administration: | Intrathecal injection; on the 4 th, 10 th, 15 th, 20 th, and 24 th days | | Result: | Significantly reduced the mechanical hypersensitivity in animals with EAE. |
| [IC 50]
N-type calcium channel | [storage]
Store at -20°C, protect from light, stored under nitrogen |
|
| Company Name: |
MOTIF BIOTECH.,Ltd
|
| Tel: |
0512-66891112-807 17805067858 |
| Website: |
www.motifbiotech.com/ |
|